Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) EPS (Basic) (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed EPS (Basic) for 4 consecutive years, with -$1.2 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 192.68% to -$1.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.85 through Dec 2025, up 39.62% year-over-year, with the annual reading at -$2.85 for FY2025, 21.79% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$1.2 at LENZ Therapeutics, down from -$0.59 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.38 in Q3 2024, with the low at -$9.62 in Q3 2023.
  • Average EPS (Basic) over 4 years is -$2.2, with a median of -$0.53 recorded in 2025.
  • The sharpest move saw EPS (Basic) plummeted 2037.78% in 2023, then soared 96.05% in 2024.
  • Over 4 years, EPS (Basic) stood at -$0.44 in 2022, then tumbled by 2086.36% to -$9.62 in 2023, then surged by 95.74% to -$0.41 in 2024, then crashed by 192.68% to -$1.2 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.2, -$0.59, and -$0.53 for Q4 2025, Q3 2025, and Q2 2025 respectively.